11607779
Descrição
Mapa Mental por Samara Watts, atualizado more than 1 year ago
|
Criado por Samara Watts
aproximadamente 7 anos atrás
|
|
Respiratory Drugs
- Bronchodilators
- B2 adrenergic agonists
- Short acting
- Salbutamol,
terbutaline
- used for actue asthma
- used for actue asthma
- Salbutamol,
terbutaline
- Long acting
- eformoterol, salmeterol
- used as a symptom controller
- used as a symptom controller
- eformoterol, salmeterol
- MOA: Stimulate B2 adrenergic receptors on the bronchial smooth muscles and
stimulates sympathetic nervous system response - causing bronchodilation.
- Adverse effects: tremors, tachycardia, headache,
increased blood glucose levels,
- Adverse effects: tremors, tachycardia, headache,
increased blood glucose levels,
- Short acting
- Antimuscarinics
- Short acting
- Ipratropium
- Ipratropium
- Long acting
- tiotropium, glycopyrronium
- tiotropium, glycopyrronium
- Theraputic action: bronchodilation, decreased mucous secretion action
- MOA: block muscarinic receptors and inhibit the parasympathetic nervous system
- Adverse reactions: dry mouth/throat irritation, blurred vision.
- Adverse reactions: dry mouth/throat irritation, blurred vision.
- MOA: block muscarinic receptors and inhibit the parasympathetic nervous system
- Short acting
- Methylxanthines
- Theophylline, aminophylline
- Theraputic action: increased cellular activity and bronchodilation
- MOA: inhibits the enzyme that degrades cAMP
- Adverse reactions: insomnia, anxiety, tremors, tachycardia, nausea
- Adverse reactions: insomnia, anxiety, tremors, tachycardia, nausea
- MOA: inhibits the enzyme that degrades cAMP
- Theraputic action: increased cellular activity and bronchodilation
- Theophylline, aminophylline
- B2 adrenergic agonists
- Preventer drug
- Leukotriene receptor antagonists
- Montelukast
- Theraputic Action: mediate inflammatory reactions
- MOA: blocks action of inflammation mediators
- Adverse effects: headache, GI upset, thirst
- Adverse effects: headache, GI upset, thirst
- MOA: blocks action of inflammation mediators
- Theraputic Action: mediate inflammatory reactions
- Montelukast
- Mast cell stabilisers
- Sodium cromoglycale
- Theraputic action: preventer group
- MOA: prevents release of inflammatory mediators
from mast cells
- Adverse effects: Throat irritation, nausea
- Adverse effects: Throat irritation, nausea
- MOA: prevents release of inflammatory mediators
from mast cells
- Theraputic action: preventer group
- Sodium cromoglycale
- Steriods
- Steroidal Anti-iinflammatory
- Systemic corticosteriods
- Prednisone, Methylprednisolone
- Prednisone, Methylprednisolone
- Inhaled corticosteriods
- Beclometasone, Fluticasone
- Beclometasone, Fluticasone
- Theraputic Action: bronchoconstriction and inflammation decreation
- MOA: inhibits rupture of mast cells, decreases inflammatory mediators,
suppresses antibody production and immune cells.
- Adverse reactions: Fluid and electrolyte imbalance, immunosuppressence
- Adverse reactions: Fluid and electrolyte imbalance, immunosuppressence
- MOA: inhibits rupture of mast cells, decreases inflammatory mediators,
suppresses antibody production and immune cells.
- Systemic corticosteriods
- Combined formulations
- Seretide & Symbicort
- Seretide & Symbicort
- Steroidal Anti-iinflammatory
- Leukotriene receptor antagonists
Quer criar seus próprios Mapas Mentais gratuitos com a GoConqr? Saiba mais.